KDM1A and small cell lung carcinoma: One ongoing Phase I/II study sponsored by the University of Washington is evaluating the effect of an orally active LSD1 inhibitor, bomedemstat (IMG-7289), and immunotherapy in patients with newly diagnosed extensive stage small cell lung cancer (Es-SCLC) (NCT05191797).